Amarantus to Present at 6th Annual Livingston Securities Life Science Stakeholders Summit
SUNNYVALE, Calif., Oct. 16, 2013 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced that President & CEO Gerald E. Commissiong will present at the 6th annual Livingston Securities Life Science Stakeholders Summit on Thursday, October 17th, 2013. The conference will be held at the offices of Akerman Senterfitt, located at 666 5th Ave in midtown Manhattan.
Information at a Glance:
WHEN: Thursday, October 17th, 2013
WHERE: Akerman Senterfitt, 666 5th Ave, Manhattan, NY.
WHO: Gerald E. Commissiong, President & CEO of Amarantus
About Livingston Securities
Livingston Securities LLC is a FINRA member investment bank/advisory and broker/dealer dedicated to providing corporate finance and strategic advisory services to corporate clients and sales, trading and related services to institutional investors and high net worth individuals who focus on nanotechnology and other emerging technologies and their impact on healthcare, energy, infrastructure and other leading sectors of the American and global economy.
Livingston Securities focuses on providing investment banking, advisory and brokerage services to a wide variety of clients, including public and private corporations, institutional and high net worth investors, governments and universities.
Amarantus is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Alzheimer's disease, Traumatic Brain Injury, and other human diseases. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.
CONTACT: Investor/Media Contacts Russell Miller, Director of Investor Relations Amarantus Bioscience Holdings, Inc. 408.737.2734 x 109 email@example.com